Armour Thyroid vs Tirosint: Titration Speed and Tolerability Compared

What Are These Two Thyroid Medications?

Armour Thyroid and Tirosint treat the same condition, hypothyroidism, but they are pharmacologically very different products. Armour Thyroid is a natural desiccated thyroid (NDT) extract from porcine thyroid glands, standardized to deliver both T4 (thyroxine) and T3 (triiodothyronine) in a fixed ratio of approximately 38 mcg T4 and 9 mcg T3 per grain (60 mg) [1]. Tirosint is a brand-name levothyroxine (synthetic T4 only) formulated as a liquid-filled gel capsule, designed to remove the fillers and dyes that can impair tablet absorption [2].

Why the Formulation Difference Matters

The presence or absence of T3 is not a trivial distinction. T3 is roughly three to four times more biologically potent than T4, and it acts faster [3]. Every dose of Armour Thyroid delivers an immediate T3 pulse that Tirosint simply does not produce. That single pharmacokinetic fact shapes every titration decision made when using either drug.

Tirosint's gel-capsule design matters for a different reason. Standard levothyroxine tablets contain acacia, lactose, and colorants that can reduce absorption in patients with GI conditions. Tirosint eliminates most of those excipients, producing measurably higher bioavailability even in patients with intact GI function [2].

Approved Indications and Available Doses

Both drugs carry FDA approval for hypothyroidism and TSH suppression in thyroid cancer. Armour Thyroid is available in grains: 0.5, 1, 1.5, 2, 3, 4, and 5 grain tablets [1]. Tirosint comes in 13 mcg increments from 13 mcg up to 150 mcg, giving clinicians finer dose-adjustment granularity [4].

Titration Speed: Which Drug Reaches Target TSH Faster?

Tirosint generally reaches a stable TSH target faster than Armour Thyroid in newly diagnosed patients. The reasons are predictable absorption and a longer T4 half-life (approximately 7 days) that allows steady-state to develop reliably at 6 to 8 weeks [3]. Armour Thyroid titration is slower in practice because each dose step changes both T4 and T3 simultaneously, and the T3 component has a half-life of only about one day, producing daily fluctuation that complicates TSH interpretation.

Titration Protocol for Tirosint

Standard Tirosint titration follows the same schedule recommended for all levothyroxine formulations by the American Thyroid Association. The starting dose in otherwise healthy adults under 60 years is typically the full replacement dose of 1.6 mcg/kg/day [5]. TSH is rechecked at 6 to 8 weeks. If the result is outside the target range (typically 0.4 to 4.0 mIU/L for most patients, 0.1 to 2.0 mIU/L for some symptomatic patients), the dose is adjusted by one increment (12.5 or 25 mcg), and TSH is repeated another 6 to 8 weeks later [5].

Because Tirosint's absorption is more consistent than tablet levothyroxine, fewer dose adjustments are often needed to hit target. Vita et al. (Endocrine, 2014) compared Tirosint to standard levothyroxine tablets in a crossover study and measured a mean 48.4% higher AUC (area under the curve) for Tirosint, with TSH suppression achieved at meaningfully lower doses in the gel-cap group [2].

Titration Protocol for Armour Thyroid

Armour Thyroid titration begins lower and moves more slowly. Most clinicians start at 0.5 to 1 grain (30 to 60 mg) daily and increase by 0.5 grain no sooner than every 4 to 6 weeks [6]. The ceiling on titration speed is not TSH alone. Clinicians must also monitor free T3, which can rise into a hyperthyroid range before TSH fully suppresses, particularly in the two to four hours immediately after the dose [7].

A clinically significant finding from Hoang et al. (J Clin Endocrinol Metab, 2013, N=70) was that patients randomized to desiccated thyroid extract showed suppressed TSH at levels consistent with mild biochemical hyperthyroidism more often than patients on levothyroxine, even when free T4 values were comparable [8]. That pattern means the titration endpoint for Armour Thyroid is a moving target: TSH alone is insufficient, and clinicians who titrate to TSH without checking free T3 risk over-treating.

Head-to-Head: Time to Stable TSH

No randomized trial has directly compared time-to-stable-TSH between Tirosint specifically and Armour Thyroid. Based on the pharmacokinetics of each drug and standard titration intervals, a reasonable clinical estimate is:

• Tirosint: 12 to 16 weeks to first stable TSH in most de-novo hypothyroid patients using the full-replacement start strategy
• Armour Thyroid: 16 to 24 weeks to stable TSH when starting low and titrating by 0.5-grain increments every 4 to 6 weeks

These estimates align with clinical experience reported in observational literature and with the pharmacokinetic data for each formulation [5][8].

Tolerability: Side Effects and Who Handles Each Drug Better

Tolerability profiles differ substantially between the two drugs, and the difference is almost entirely attributable to T3. Armour Thyroid produces T3 peaks that can cause palpitations, anxiety, heat intolerance, and insomnia in susceptible patients. These symptoms often appear 1 to 2 hours after the morning dose and resolve by afternoon [7]. Tirosint, as a T4-only formulation, does not produce the same acute T3 peaks.

T3-Related Side Effects With Armour Thyroid

The serum T3 peak following a single grain of Armour Thyroid can exceed the upper limit of the normal reference range transiently. Patients with pre-existing anxiety disorders, atrial fibrillation risk, or cardiovascular disease are particularly vulnerable. The American Thyroid Association's 2014 guidelines note that "the fixed ratio of T4 to T3 in desiccated thyroid preparations may not replicate normal thyroid secretion in all patients" and advise caution in patients with heart disease [5].

Splitting the Armour Thyroid dose into twice-daily administration reduces peak T3 by approximately 30 to 40% and is the most common strategy to improve tolerability without switching drugs [6]. Twice-daily dosing is not universally effective, and some patients still report symptomatic T3 surges even on split doses.

Tolerability Advantages of Tirosint

Tirosint's primary tolerability advantage is its excipient profile. The gel capsule contains only glycerin, gelatin, and water alongside the levothyroxine sodium [4]. There is no lactose, no gluten, no acacia, and no dyes. For patients with lactose intolerance, celiac disease, or dye sensitivities, this formulation eliminates a common source of GI complaints attributed to thyroid medication.

A secondary benefit is consistency. Because Tirosint is absorbed more reliably, patients are less likely to experience the symptom swings associated with variable levothyroxine absorption from tablets taken with food, coffee, or calcium supplements. The FDA label for Tirosint advises the same 30 to 60 minute pre-meal window as standard levothyroxine [4], but real-world data suggest less sensitivity to co-administration timing with Tirosint compared to tablets [2].

Patients Who Report Better Outcomes on Armour Thyroid

Despite the tolerability challenges, a subset of patients report meaningfully better subjective wellbeing on Armour Thyroid than on any levothyroxine product. Hoang et al. (2013) found that 49% of their 70-patient cohort preferred desiccated thyroid extract over levothyroxine, citing better mood, energy, and cognition, even though objective thyroid function tests did not differ significantly between groups [8]. Body weight was also modestly lower in the NDT group (a mean 0.4 kg difference, which was statistically significant at P<0.01) [8].

The mechanism behind subjective preference is not fully understood. One hypothesis involves the direct T3 delivery bypassing peripheral T4-to-T3 conversion, which may be impaired in some patients due to deiodinase enzyme polymorphisms [9].

Absorption and Bioavailability: Why Tirosint Has an Edge

Bioavailability is where Tirosint most clearly outperforms both standard levothyroxine tablets and Armour Thyroid. Armour Thyroid's T4 component has a reported oral bioavailability of approximately 40 to 60%, comparable to standard levothyroxine tablets [3]. Tirosint's bioavailability in the Vita et al. Crossover study was significantly higher, with the gel capsule producing a 48.4% greater AUC than the equivalent tablet dose [2].

Implications for Patients With GI Conditions

Patients with atrophic gastritis, H. Pylori infection, bariatric surgery history, or inflammatory bowel disease absorb standard levothyroxine tablets poorly. Tirosint was developed in part for this population. Because the drug is pre-dissolved in the gel capsule, it does not require gastric acid for dissolution. Armour Thyroid, by contrast, is a compressed tablet and depends on normal gastric function for dissolution and absorption [1][3].

For patients post-bariatric surgery, Tirosint's pre-dissolved formulation may be the more rational choice over any compressed tablet, including Armour Thyroid [4][10].

Drug and Food Interactions Affecting Absorption

Both formulations are affected by calcium, iron, antacids, and proton pump inhibitors, though Tirosint appears less sensitive. The standard interaction guidance applies to both: separate thyroid hormone from calcium by 4 hours and from iron by at least 4 hours [5]. Coffee impairs levothyroxine tablet absorption by up to 36% but has a smaller effect on Tirosint based on the bioavailability data [2][11].

Switching From Armour Thyroid to Tirosint

Switching from Armour Thyroid to Tirosint is one of the more common transitions in thyroid practice, particularly when patients on NDT develop cardiovascular symptoms, require finer dose control, or experience inconsistent labs. The switch requires dose conversion, a monitoring plan, and patient counseling about what to expect in the weeks after the change.

Dose Conversion Guidance

A standard conversion uses the T4 equivalency of Armour Thyroid. Each grain (60 mg) of Armour Thyroid contains approximately 38 mcg T4. A patient on 2 grains (120 mg) of Armour Thyroid is receiving approximately 76 mcg T4-equivalent, which maps to a starting Tirosint dose of 75 or 88 mcg depending on rounding and the prescriber's clinical judgment [1][5].

Because the T3 component of Armour Thyroid is lost in the switch, some patients will feel transiently more fatigued or mentally sluggish for 2 to 6 weeks after conversion, even when the T4 dose is appropriate. This is normal and usually self-resolves as the body adjusts to T4-only therapy and peripheral conversion stabilizes [8].

Monitoring After the Switch

TSH and free T4 should be checked 6 to 8 weeks after converting to Tirosint. If a patient was on a suppressed TSH with Armour Thyroid (which is common given the T3-induced TSH suppression noted by Hoang et al.), the TSH may rise initially on Tirosint even at an equivalent T4 dose [8]. This does not necessarily mean the Tirosint dose is insufficient. Free T4 and free T3 levels together provide a more complete picture during the transition period.

A practical clinical framework for the switch:

1. Calculate T4-equivalent dose from current Armour Thyroid grains (multiply grains by 38 mcg T4).
2. Select the nearest available Tirosint dose, rounding down if the patient has any history of palpitations or anxiety on Armour.
3. Check TSH and free T4 at 6 to 8 weeks.
4. If TSH is above 2.5 mIU/L and the patient is symptomatic, increase Tirosint by 12.5 mcg.
5. Recheck TSH at 6 to 8 weeks. Repeat until stable.

Switching From Tirosint Back to Armour Thyroid

The reverse switch is less common and is usually requested by patients who feel their quality of life was better on NDT. Conversion in this direction uses the same T4-equivalency math, but the prescriber should account for the added T3 by starting at the lower grain increment. A patient stabilized on 100 mcg Tirosint (approximately 2.6 grains T4-equivalent) would typically start at 2 grains of Armour Thyroid and titrate from there [1][6].

Patient Selection: Who Should Be on Which Drug?

Not every hypothyroid patient is a candidate for both formulations. Clinical characteristics, comorbidities, and patient-reported preferences all shape the choice.

Patients Who May Do Better on Tirosint

• History of irregular levothyroxine absorption (bariatric surgery, celiac disease, atrophic gastritis)
• Allergy or intolerance to tablet dyes, lactose, or gluten
• Cardiac arrhythmia, paroxysmal atrial fibrillation, or angina (avoids T3 peaks)
• Patients requiring tight TSH control for thyroid cancer surveillance
• Patients who need finer dose increments than standard tablets offer

Patients Who May Do Better on Armour Thyroid

• Persistent hypothyroid symptoms despite optimized TSH and free T4 on levothyroxine [8]
• Self-reported cognitive symptoms, fatigue, or mood disturbance attributed to T4-only therapy
• Patients with possible deiodinase type-2 polymorphism affecting T4-to-T3 conversion [9]
• Patients who prefer a non-synthetic, animal-derived product

The 2019 American Thyroid Association task force report on combination T4/T3 therapy acknowledged that a subset of patients report better quality of life on NDT or on combination therapy, and that clinician dismissal of these preferences is not supported by evidence [12].

Cost, Insurance, and Practical Access

Armour Thyroid is a branded NDT product but has been available for decades and is generally covered by most commercial insurance plans. Generic desiccated thyroid (NP Thyroid, Nature-Throid) offers a lower-cost alternative to the same pharmacological class. Tirosint is a branded product with no generic equivalent in gel-capsule form as of 2025, and it carries a higher out-of-pocket cost than generic levothyroxine tablets [4].

Patients without insurance coverage may pay $80, $150 per month for Tirosint versus $10, $30 for generic levothyroxine tablets. Manufacturer copay assistance programs for Tirosint are available and can reduce cost to under $30/month for eligible patients [4]. Armour Thyroid runs approximately $40, $80 per month at standard doses without insurance.

Summary Table: Armour Thyroid vs Tirosint at a Glance

| Feature | Armour Thyroid | Tirosint | |---|---|---| | Active hormones | T4 + T3 | T4 only | | T3 per grain | ~9 mcg per 60 mg grain | None | | Titration interval | Every 4 to 6 weeks | Every 6 to 8 weeks | | Typical titration duration | 16 to 24 weeks | 12 to 16 weeks | | Bioavailability (T4) | ~40 to 60% | ~48.4% higher AUC vs tablet [2] | | Excipients | Dextrose, coloring agents | Glycerin, gelatin, water only | | GI condition suitability | Moderate | High | | Cardiac risk concern | Higher (T3 peaks) | Lower | | Cost without insurance | $40, $80/month | $80, $150/month | | Patient preference data | 49% prefer NDT in Hoang 2013 [8] | No direct preference trial |